None listed
Conditions
Interventions
Drug : 1. Drug Name: Terazosin HCl 2 mg (Hytrin Tab. 2mg)
2. Administration dose: 4 mg
3. Number of doses: q.d.
4. Duration of administration: 16 weeks
5. Injection route: oral administration
Sponsors
Hallym University Medical Center
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: ? Men over 19 ? Those who have had pelvic pain for at least 3 months within the last 6 months ? Those who have an The National Institutes of Health Chronic Prostatitis Symptom Index(NIH-CPSI) score of 15 or higher ? Those who have 8 or more International Prostate Symptom Score(IPSS) score ? A person who voluntarily decides to participate in this study and agrees in writing to the subject's consent
Exclusion criteria
Exclusion criteria: ? Persons with hypersensitivity to hytrine-based drugs (a-blocker) ? Those who are taking cholinergic drugs and diuretics ? Those with urination disorders due to obvious causes other than enlarged prostate ? Those with urinary tract infection (midstream urine culture> 100,000 colonies / mL) ? Patients with clinically significant circulatory diseases (myocardial infarction, heart failure, angina pectoris, deep vein, pacemaker use, orthostatic hypotension, uncontrolled hypotension) ? Participants in other interventional clinical trials within 3 months of screening ? Those who have a past or present history of malignant tumors and are inappropriate for participation in research when judged by the research director or the person in charge of the research ? Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption ? Other persons who are inappropriate to participate in research as judged by the research director or research manager
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of prostate symptoms improvement at week 12 relative to baseline (IPSS) | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of improvement of prostatitis symptoms at week 12 compared to baseline (NIH-CPSI);Assessment of prostate symptoms improvement at week 6 relative to baseline (IPSS);Evaluation of improvement of prostatitis symptoms at week 6 compared to baseline (NIH-CPSI) | — |
Countries
Korea, Republic of
Contacts
Public ContactWoo Jin Bang
Hallym University Medical Center
Outcome results
None listed